

## 11. LITERATURVERZEICHNIS

1. *Pschyrembel Klinisches Wörterbuch*. 258. Auflage ed. Berlin: Walter de Gruyter; 1998.
2. Pearson T. *The social system*: Glencoe; 1951.
3. Organisation WH. *Measurement of levels of health: Report of a study group*: World Health Organisation; 2001/07/09 1957. WHO Technical Report Series, No. 137.
4. Tarlov AR, Ware JE, Greenfield S, al. e. The Medical Outcomes Study: An application of methods for monitoring the results of medical care. *J Am Med Ass*. 2001/07/07 1983;262:925-932.
5. Lindstrom B. Quality of life: a model for evaluating health for all. Conceptual considerations and policy implications. *Soz Praventivmed*. 1992;37(6):301-306.
6. Gill TM, Feinstein AR. A critical appraisal of the quality of quality-of-life measurements. *Jama*. 1994;272(8):619-626.
7. The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization. *Soc Sci Med*. 1995;41(10):1403-1409.
8. Radoschewski M. Gesundheitsbezogene Lebensqualität - Konzepte und Maße. *Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz*. 2001/07/09 2000;45:165-189.
9. McDowell I, Newell C. A guide to rating scales and questionnaires. *Measuring health*. New York: Oxford University Press; 1987.
10. Anderson RT, Aaronson NK, Bullinger M, McBee WL. A review of the progress towards developing health-related quality-of- life instruments for international clinical studies and outcomes research. *Pharmacoeconomics*. 1996;10(4):336-355.
11. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care*. 1992;30(6):473-483.
12. Hunt SM, McKenna SP, McEwen J, Williams J, Papp E. The Nottingham Health Profile: subjective health status and medical consultations. *Soc Sci Med [A]*. 1981;15(3 Pt 1):221-229.
13. Ringdal GI, Ringdal K. Testing the EORTC Quality of Life Questionnaire on cancer patients with heterogeneous diagnoses. *Qual Life Res*. 1993;2(2):129-140.
14. Anderson JP, Kaplan RM, Coons SJ, Schneiderman LJ. Comparison of the Quality of Well-being Scale and the SF-36 results among two samples of ill adults: AIDS and other illnesses. *J Clin Epidemiol*. 1998;51(9):755-762.

15. Bergner M, Bobbitt RA, Carter WB, Gilson BS. The Sickness Impact Profile: development and final revision of a health status measure. *Med Care*. 1981;19(8):787-805.
16. Schuntermann MF. [The Duke Health Profile (DUKE)]. *Rehabilitation (Stuttg)*. 1997;36(1):I-XIV.
17. Ware JE, Jr., Snow K, K., Kosinski M, Gandek B. *SF-36 Health survey. Manual and Interpretation guide*. Boston, Mass.: The Health Institute, New England Medical Center; 1993.
18. Ware JE, Jr., Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. *J Clin Epidemiol*. 1998;51(11):903-912.
19. Gandek B, Ware JE, Jr., Aaronson NK, et al. Tests of data quality, scaling assumptions, and reliability of the SF- 36 in eleven countries: results from the IQOLA Project. International Quality of Life Assessment. *J Clin Epidemiol*. 1998;51(11):1149-1158.
20. Bullinger M, Kirchberger I. *Der SF-36 Fragebogen zum Gesundheitszustand. Handbuch für die deutschsprachige Fragebogenversion*. Göttingen: Hogrefe-Verlag für Psychologie; 1998.
21. Bullinger M, Alonso J, Apolone G, et al. Translating health status questionnaires and evaluating their quality: the IQOLA Project approach. International Quality of Life Assessment. *J Clin Epidemiol*. 1998;51(11):913-923.
22. Gandek B, Ware JE, Jr. Methods for validating and norming translations of health status questionnaires: the IQOLA Project approach. International Quality of Life Assessment. *J Clin Epidemiol*. 1998;51(11):953-959.
23. Hemingway H, Stafford M, Stansfeld S, Shipley M, Marmot M. Is the SF-36 a valid measure of change in population health? Results from the Whitehall II Study. *Bmj*. 1997;315(7118):1273-1279.
24. Ellert U, Bellach BM. [The SF-36 in the Federal Health Survey--description of a current normal sample]. *Gesundheitswesen*. 1999;61 Spec No:S184-190.
25. Bullinger M. [Assessment of health related quality of life with the SF-36 Health Survey]. *Rehabilitation (Stuttg)*. 1996;35(3):XXVII-XXVII; quiz XXVII-XXIX.
26. Weinberger M, Oddone EZ, Samsa GP, Landsman PB. Are health-related quality-of-life measures affected by the mode of administration? *J Clin Epidemiol*. 1996;49(2):135-140.

27. Beaton DE, Hogg-Johnson S, Bombardier C. Evaluating changes in health status: reliability and responsiveness of five generic health status measures in workers with musculoskeletal disorders. *J Clin Epidemiol.* 1997;50(1):79-93.
28. Hadorn DC, Sorensen J, Holte J. Large-scale health outcomes evaluation: how should quality of life be measured? Part II--Questionnaire validation in a cohort of patients with advanced cancer. *J Clin Epidemiol.* 1995;48(5):619-629.
29. Hadorn DC, Uebersax J. Large-scale health outcomes evaluation: how should quality of life be measured? Part I--Calibration of a brief questionnaire and a search for preference subgroups. *J Clin Epidemiol.* 1995;48(5):607-618.
30. Bullinger M. *Der SF-36 Fragebogen zum Gesundheitszustand. Handbuch für die deutschsprachige Fragebogenversion.*: Medical Outcome Trust; 1995.
31. McHorney CA, Haley SM, Ware JE, Jr. Evaluation of the MOS SF-36 Physical Functioning Scale (PF-10): II. Comparison of relative precision using Likert and Rasch scoring methods. *J Clin Epidemiol.* 1997;50(4):451-461.
32. Lyons RA, Fielder H, Littlepage BN. The SF 36 health survey questionnaire. Questionnaire does not detect poor sleep. *Bmj.* 1993;307(6901):449.
33. Porzolt F, Wölpl CP, Rist CE, Kosa R, Büchele G, Gaus W. Vergleich von drei Instrumenten, die gesundheitsbezogene Lebensqualität / Qualität von Wohlbefinden messen. QLQ-C30, SF-36, QWB-7. In: Weißenbach L, Biermann CW, eds. *Derzeitiger Stand und Aspekte der Lebensqualitätsforschung in der urologischen Onkologie.* München, Bern, Wien, New York: Zuckschwerdt Verlag; 1997:586-609.
34. Singleton N, Turner A. Measuring patients' views of their health. SF 36 is suitable for elderly patients. *Bmj.* 1993;307(6896):126-127.
35. Hayes V, Morris J, Wolfe C, Morgan M. The SF-36 health survey questionnaire: is it suitable for use with older adults? *Age Ageing.* 1995;24(2):120-125.
36. Keen H. The Diabetes Control and Complications Trial (DCCT). *Health Trends.* 1994;26(2):41-43.
37. Jacobson AM. Quality of Life in Patients With Diabetes Mellitus. *Semin Clin Neuropsychiatry.* 1997;2(1):82-93.
38. Jacobson AM, de Groot M, Samson JA. The evaluation of two measures of quality of life in patients with type I and type II diabetes. *Diabetes Care.* 1994;17(4):267-274.
39. Shen W, Kotsanos JG, Huster WJ, Mathias SD, Andrejasich CM, Patrick DL. Development and validation of the Diabetes Quality of Life Clinical Trial Questionnaire. *Med Care.* 1999;37(4 Suppl Lilly):AS45-66.

40. Ziegler D, Gries FA. Diabetische Neuropathie. In: Wäldhäusl W, ed. *Diabetes in der Praxis*. Vol 32. 2. Auflage ed. Berlin: Springer; 1996:342-356.
41. Glocker FX, Seifert C. Erworbene Polyneuropathien. In: Hufschmidt A, Lücking CH, eds. *Neurologie compact : Leitlinien für Klinik und Praxis*. Vol 2. aktualisierte und erw. Auflage. Stuttgart: Thieme Verlag; 1999:247-250.
42. Ziegler D. Pathogenese der diabetischen Neuropathie. *Diabetes und Stoffwechsel*. 1998;7:251-266.
43. Maser RE, Nielsen VK, Bass EB, et al. Measuring diabetic neuropathy. Assessment and comparison of clinical examination and quantitative sensory testing. *Diabetes Care*. 1989;12(4):270-275.
44. Franklin GM, Kahn LB, Baxter J, Marshall JA, Hamman RF. Sensory neuropathy in non-insulin-dependent diabetes mellitus. The San Luis Valley Diabetes Study. *Am J Epidemiol*. 1990;131(4):633-643.
45. Ziegler D. Diabetic cardiovascular autonomic neuropathy: prognosis, diagnosis and treatment. *Diabetes Metab Rev*. 1994;10(4):339-383.
46. Gerritsen J, Dekker JM, TenVoorde BJ, et al. Impaired Autonomic Function Is Associated With Increased Mortality, Especially in Subjects With Diabetes, Hypertension, or a History of Cardiovascular Disease: The Hoorn Study. *Diabetes Care*. 2001;24(10):1793-1798.
47. Chen HS, Hwu CM, Kuo BI, et al. Abnormal cardiovascular reflex tests are predictors of mortality in Type 2 diabetes mellitus. *Diabet Med*. 2001;18(4):268-273.
48. Ziegler D, Dannehl K, Muhlen H, Spuler M, Gries FA. Prevalence of cardiovascular autonomic dysfunction assessed by spectral analysis, vector analysis, and standard tests of heart rate variation and blood pressure responses at various stages of diabetic neuropathy. *Diabet Med*. 1992;9(9):806-814.
49. Malik M, Camm AJ. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology [see comments]. *Circulation*. Mar 1 1996;93(5):1043-1065.
50. Hales S. Haemastatics. In: S H, ed. *Statistical Essays*. Vol 2. London: Innys and Manby; 1735:1-86.
51. Akselrod S. Components of heart rate variability. In: Malik M, Camm AJ, eds. *Heart rate variability*. Vol 12. Armonk, NY: Futura; 1995:147-164.

52. Mayer S. Studien zur Physiologie des Herzens und der Blutgefäße - 5. Abhandlung: Über spontane Blutdruckschwankungen. *Sber Akad Wiss Wien*. 1876(74):281-307.
53. Wenckebach KF, Winterberger. *Die unregelmäßige Herztätigkeit*. Leipzig; 1927.
54. Schlomka G, Buschmann W, Schulte-Kruppen T. Über die Abhängigkeit der respiratorischen (Ruhe-)Arrhythmie von der Schlagfrequenz und vom Lebensalter. *Z Kreislaufforsch*. 1937;29:510-524.
55. Hon EH, Lee ST. Electronic evaluations of the fetal heart rate patterns preceding fetal death: further observations. *Am J Obstet Gynecol*. 1965;87:814-826.
56. Rohmert W, Laurig W, Philipp U, Luczak H. Heart rate variability and work-load measurement. *Ergonomics*. 1973;16(1):33-44.
57. Luczak H, Laurig W. An analysis of heart rate variability. *Ergonomics*. 1973;16(1):85-97.
58. Opmeer CH. The information content of successive RR-interval times in the ECG. Preliminary results using factor analysis and frequency analysis. *Ergonomics*. 1973;16(1):105-112.
59. Penaz J, Roukenz J, Van der Waal HJ. In: Drischel H, Tiedt N, eds. *Spectral Analysis of Some Spontaneous Rhythms in the Circulation*. Leipzig, Germany: Biokybernetik, Karl Marx University; 1968:233-241.
60. Sayers BM. Analysis of heart rate variability. *Ergonomics*. 1973;16(1):17-32.
61. Ewing DJ, Campbell IW, Burt AA, Clarke BF. Vascular reflexes in diabetic autonomic neuropathy. *Lancet*. 1973;2(7842):1354-1356.
62. Ewing DJ, Martyn CN, Young RJ, Clarke BF. The value of cardiovascular autonomic function tests: 10 years experience in diabetes. *Diabetes Care*. 1985;8(5):491-498.
63. Wolf MM, Varigos GA, Hunt D, Sloman JG. Sinus arrhythmia in acute myocardial infarction. *Med J Aust*. 1978;2(2):52-53.
64. Akselrod S, Gordon D, Ubel FA, Shannon DC, Berger AC, Cohen RJ. Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat-to-beat cardiovascular control. *Science*. 1981;213(4504):220-222.
65. Kleiger RE, Miller JP, Bigger JT, Jr., Moss AJ. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. *Am J Cardiol*. 1987;59(4):256-262.
66. Malik M, Farrell T, Cripps T, Camm AJ. Heart rate variability in relation to prognosis after myocardial infarction: selection of optimal processing techniques. *Eur Heart J*. 1989;10(12):1060-1074.

67. Fei L. Effects of pharmacological interventions on heart rate variability: Animal experiments and clinical observations. In: Malik M, Camm AJ, eds. *Heart rate variability*. Vol 22. Armonk, NY.: Futura; 1995:275-291.
68. Vardas PE, Kanoupakis EM, Kochiadakis GE, Simantirakis EN, Marketou ME, Chlouverakis GI. Effects of long-term digoxin therapy on heart rate variability, baroreceptor sensitivity, and exercise capacity in patients with heart failure. *Cardiovasc Drugs Ther*. 1998;12(1):47-55.
69. Kontopoulos AG, Athyros VG, Papageorgiou AA, Skeberis VM, Basayiannis EC, Boudoulas H. Effect of angiotensin-converting enzyme inhibitors on the power spectrum of heart rate variability in post-myocardial infarction patients. *Coron Artery Dis*. 1997;8(8-9):517-524.
70. Salo TM, Kantola I, Voipio-Pulkki LM, Pelttari L, Viikari JS. The effect of four different antihypertensive medications on cardiovascular regulation in hypertensive sleep apneic patients--assessment by spectral analysis of heart rate and blood pressure variability. *Eur J Clin Pharmacol*. 1999;55(3):191-198.
71. Vaile JC, Chowdhary S, Osman F, et al. Effects of angiotensin II (AT1) receptor blockade on cardiac vagal control in heart failure. *Clin Sci (Lond)*. 2001;101(6):559-566.
72. Andresen D, Brüggemann T, Behrens S, Ehlers C. Heart rate response to provocative maneuvers. In: Malik M, Camm AJ, eds. *Heart rate variability*. Vol 21. Armonk, NY: Futura; 1995:267-274.
73. Agelink MW, Malessa R, Baumann B, et al. Standardized tests of heart rate variability: normal ranges obtained from 309 healthy humans, and effects of age, gender, and heart rate. *Clin Auton Res*. 2001;11(2):99-108.
74. Huikuri HV, Makikallio TH, Peng CK, Goldberger AL, Hintze U, Moller M. Fractal correlation properties of R-R interval dynamics and mortality in patients with depressed left ventricular function after an acute myocardial infarction [see comments]. *Circulation*. 2000;101(1):47-53.
75. Blaber AP, Bondar RL, Freeman R. Coarse graining spectral analysis of HR and BP variability in patients with autonomic failure. *Am J Physiol*. 1996;271(4 Pt 2):H1555-1564.
76. Butler GC, Yamamoto Y, Hughson RL. Heart rate variability to monitor autonomic nervous system activity during orthostatic stress. *J Clin Pharmacol*. 1994;34(6):558-562.

77. Murray A, Ewing DJ, Campbell IW, Neilson JM, Clarke BF. RR interval variations in young male diabetics. *Br Heart J*. 1975;37(8):882-885.
78. Pagani M, Malfatto G, Pierini S, et al. Spectral analysis of heart rate variability in the assessment of autonomic diabetic neuropathy. *J Auton Nerv Syst*. 1988;23(2):143-153.
79. Malpas SC, Maling TJ. Heart-rate variability and cardiac autonomic function in diabetes. *Diabetes*. 1990;39(10):1177-1181.
80. Bellavere F. Heart rate variability in patients with diabetes and other noncardiological diseases. In: Malik M, Camm AJ, eds. *Heart rate variability*. Armonk, NY: Futura; 1995:507-516.
81. Malliani A, Pagani M, Lombardi F. Importance of appropriate spectral methodology to assess heart rate variability in the frequency domain [letter; comment]. *Hypertension*. 1994;24(1):140-142.
82. Spallone V, Menzinger G. Diagnosis of cardiovascular autonomic neuropathy in diabetes. *Diabetes*. 1997;46(Suppl 2):S67-76.
83. Howorka K, Pumprla J, Schabmann A, Thoma H. [Development of an analytic standard for evaluating heart rate variability in cardiovascular autonomic neuropathy in diabetes: comparison of short-term spectral analysis with Ewing's standard battery of reflex tests as reference method]. *Biomed Tech (Berl)*. 1998;43(Suppl):568-569.
84. May O, Arildsen H. Assessing cardiovascular autonomic neuropathy in diabetes mellitus: how many tests to use? *J Diabetes Complications*. 2000;14(1):7-12.
85. Hildebrandt P, Mehlsen J, Sestoft L, Nielsen SL. Mild mental stress in diabetes: changes in heart rate and subcutaneous blood-flow. *Clin Physiol*. 1985;5(4):371-376.
86. Langewitz W, Ruddel H. Spectral analysis of heart rate variability under mental stress. *J Hypertens Suppl*. 1989;7(6):S32-33.
87. Locatelli A, Franzetti I, Lepore G, et al. Mental arithmetic stress as a test for evaluation of diabetic sympathetic autonomic neuropathy. *Diabet Med*. 1989;6(6):490-495.
88. Becker LC, Pepine CJ, Bonsall R, et al. Left ventricular, peripheral vascular, and neurohumoral responses to mental stress in normal middle-aged men and women. Reference Group for the Psychophysiological Investigations of Myocardial Ischemia (PIMI) Study. *Circulation*. 1996;94(11):2768-2777.
89. Hoshikawa Y, Yamamoto Y. Effects of Stroop color-word conflict test on the autonomic nervous system responses. *Am J Physiol*. 1997;272(3 Pt 2):H1113-1121.

90. Ahroni JH, Boyko EJ. Responsiveness of the SF-36 among veterans with diabetes mellitus. *J Diabetes Complications*. 2000;14(1):31-39.
91. Hanninen J, Takala J, Keinanen-Kiukaanniemi S. Quality of life in NIDDM patients assessed with the SF-20 questionnaire. *Diabetes Res Clin Pract*. 1998;42(1):17-27.
92. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). U.K. Prospective Diabetes Study Group. *Diabetes Care*. 1999;22(7):1125-1136.
93. Schiel R, Muller UA. Intensive or conventional insulin therapy in type 2 diabetic patients? A population-based study on metabolic control and quality of life (The JEVIN-trial). *Exp Clin Endocrinol Diabetes*. 1999;107(8):506-511.
94. Barron SA, Rogovski Z, Kanter Y, Hemli Y. Parasympathetic autonomic neuropathy in diabetes mellitus: the heart is denervated more often than the pupil. *Electromyogr Clin Neurophysiol*. 1994;34(8):467-469.
95. Yoshioka K, Terasaki J. Relationship between diabetic autonomic neuropathy and peripheral neuropathy as assessed by power spectral analysis of heart rate variations and vibratory perception thresholds. *Diabetes Res Clin Pract*. 1994;24(1):9-14.
96. Michel J, Cammann H, Uhlmann H. Computerized dynamic electrocardio-respirography with psychic load: New possibilities for preventive health care. *Medinfo 95 Proceedings, North-Holland, Amsterdam*. 1995:733-737.
97. Reichard P, Jensen-Urstad K, Ericsson M, Jensen-Urstad M, Lindblad LE. Autonomic neuropathy--a complication less pronounced in patients with Type 1 diabetes mellitus who have lower blood glucose levels. *Diabet Med*. 2000;17(12):860-866.
98. Howorka K, Pumprla J, Haber P, Koller-Strametz J, Mondrzyk J, Schabmann A. Effects of physical training on heart rate variability in diabetic patients with various degrees of cardiovascular autonomic neuropathy. *Cardiovasc Res*. 1997;34(1):206-214.
99. Liao D, Sloan RP, Cascio WE, et al. Multiple metabolic syndrome is associated with lower heart rate variability. The Atherosclerosis Risk in Communities Study. *Diabetes Care*. 1998;21(12):2116-2122.
100. Squadrito G, Cucinotta D. The late complications of diabetes mellitus. *Ann Ital Med Int*. 1991;6(1 Pt 2):126-136.